

## DESCRIPTION

<b>Species Reactivity</b>	Human/Mouse/Rat
<b>Specificity</b>	Detects human, mouse, and rat Paxillin in Western blots.
<b>Source</b>	Polyclonal Sheep IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant human Paxillin Asn59-Ser274 Accession # P49023
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.


## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	1 µg/mL	See Below
<b>Immunocytochemistry</b>	5-15 µg/mL	See Below
<b>Simple Western</b>	50 µg/mL	See Below


## DATA

### Western Blot




**Detection of Human/Mouse/Rat Paxillin by Western Blot.** Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line, CCD-1070Sk human foreskin fibroblast cell line, A431 human epithelial carcinoma cell line, HepG2 human hepatocellular carcinoma cell line, and MCF-7 human breast cancer cell line. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human/Mouse/Rat Paxillin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4259) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific diffuse band was detected for Paxillin at approximately 65 to 70 kDa (as indicated). This experiment was conducted using [Immunoblot Buffer Group 1](#).

### Immunocytochemistry



**Paxillin in HUVEC Human Cells.** Paxillin was detected in immersion fixed HUVEC human umbilical vein endothelial cells using Sheep Anti-Human/Mouse/Rat Paxillin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4259) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (red; Catalog # NL010) and counterstained with DAPI (blue). Specific staining was localized to actin filament tips and cytosol. View our protocol for [Fluorescent ICC Staining of Cells on Coverslips](#).

### Simple Western



**Detection of Human Paxillin by Simple Western™.** Simple Western lane view shows lysates of HeLa human cervical epithelial carcinoma cell line and MCF-7 human breast cancer cell line, loaded at 0.2 mg/mL. Specific bands were detected for Paxillin at approximately 70 & 69 kDa (as indicated) using 50 µg/mL of Sheep Anti-Human/Mouse/Rat Paxillin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4259). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

The cytoskeletal adaptor protein Paxillin is found at the interface between actin filaments and the plasma membrane. Paxillin localizes to focal adhesions, where it provides a platform for the integration and coordination of adhesion- and growth factor-related signals. Paxillin phosphorylation is required for integrin-mediated cytoskeletal reorganization, and may play a role in the disassembly of focal adhesions and stress fibers during cellular transformation. Increased Paxillin protein levels have also been reported in several malignancies, including renal, lung, and breast carcinomas.